0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LRRC15

LRRC15

Brief Information

Name:Leucine-rich repeat-containing protein 15
Target Synonym:LRRC15,Leucine-rich repeat-containing protein 15,hLib,Leucine Rich Repeat Containing 15,Leucine-Rich Repeat Protein Induced By Beta-Amyloid Homolog,LIB,Leucine-Rich Repeat Protein Induced By Beta Amyloid
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Pending

Product ListCompare or Buy

Part of Bioactivity data

LR5-M82E6-ELISA
Biotinylated Mouse LRRC15, His,AvitagBiotinylated Mouse LRRC15, His,Avitag (Cat. No. LR5-M82E6) ELISA bioactivity

Immobilized Biotinylated Mouse LRRC15, His,Avitag (Cat. No. LR5-M82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Samrotamab with a linear range of 0.1-1 ng/mL (QC tested).

LR5-H82E4-MALS-HPLC
Biotinylated Human LRRC15, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human LRRC15, His,Avitag (Cat. No. LR5-H82E4) was more than 90% and the molecular weight of this protein is around 80-90 kDa verified by SEC-MALS.

  • Background
    LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

Leucine-rich repeat-containing protein 15,LRRC15,LIB,hLib

Background

LRRC15 (Leucine-rich repeat-containing protein 15) is also known as LIB and hLib. LRRC15 is highly expressed in a variety of solid tumors. LRRC15 was expressed on stromal fibroblasts in many solid tumors (e.g., breast, head and neck, lung, pancreatic) as well as directly on a subset of cancer cells of mesenchymal origin (e.g., sarcoma, melanoma, glioblastoma). LRRC15 expression was induced by TGFβ on activated fibroblasts (αSMA+) and on mesenchymal stem cells. These collective findings suggested LRRC15 as a novel CAF and mesenchymal marker with utility as a therapeutic target for the treatment of cancers with LRRC15-positive stromal desmoplasia or cancers of mesenchymal origin. ABBV-085 is a monomethyl auristatin E (MMAE)-containing antibody–drug conjugate (ADC) directed against LRRC15, and it demonstrated robust preclinical efficacy against LRRC15 stromal-positive/cancer-negative, and LRRC15 cancer-positive models as a monotherapy, or in combination with standard-of-care therapies.

Clinical and Translational Updates

This web search service is supported by Google Inc.

totop